TABLE 1.

Characteristics of patients enrolled in this study

Cohort	Patient #	Sex	Age	PS*	Prior Rx†	Sites of disease‡
1	1	F	35	1	RSCI	AX, BO, IL, LI, LU, SU
1	2	M	37	0	RSCHI	AX, LI, LU, SU
1	3	M	52	0	SI	AX, LI, RP
2	4	M	57	0	SCI	LU
2	5	F	52	0	SI	LI, LU
2	6	M	48	0	RSCI	AB, BN, LU, MO, NK
3	7	M	39	0	SCI	ME, SU
3	8	F	57	0	SCI	IL, IN, SK
3	9	M	31	0	SCI	ME, PL
4	10	M	37	0	SI	LU, SU
4	11	F	32	0	RSI	AX, CL, MT, PV
4	12	M	18	0	SCI	LI, SP
4	13	M	53	0	SCI	LU, SK
4	14	F	30	1	RSCI	SK, SU
4	15	F	43	0	SI	LU, SK, SU

^*Performance status—Eastern Cooperative Oncology Group performance scale.

^†Prior treatments by category: R, radiation therapy; S, surgery; C, chemotherapy; H, hormone therapy; I, immunotherapy.

^‡Sites of evaluable disease: AB, abdominal; AX, axillary nodes; BN, brain; BO, bone; CL, supraclavicular nodes; IL, iliac nodes; IN, inguinal nodes; LI, liver; LU, lungs; ME, mediastinal; MO, mouth; MT, mesenteric; NK, neck; PL, pleura; PV, pelvis; RP, retroperitoneal; SK, skin; SP, spleen; SU, subcutaneous.